The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation

J. A. Coulter, H. O. McCarthy, Jenny Worthington, T. Robson, S. Scott, D. G. Hirst

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    Driving high-level transgene expression in a tumour-specific manner remains a key requirement in the development of cancer gene therapy. We have previously demonstrated the strong anticancer effects of generating abnormally high levels of intracellular NO center dot following the overexpression of the inducible nitric oxide synthase (iNOS) gene. Much of this work has focused on utilizing exogenously activated promoters, which have been primarily induced using X-ray radiation. Here we further examine the potential of the pE9 promoter, comprising a combination of nine CArG radio-responsive elements, to drive the iNOS transgene. Effects of X-ray irradiation on promoter activity were compared in vitro under normoxic conditions and various degrees of hypoxia. The pE9 promoter generated high-level transgene expression, comparable with that achieved using the constitutively driven cytomegalovirus promoter. Furthermore, the radio-resistance of radiation-induced fibrosarcoma-1 (RIF-1) mouse sarcoma cells exposed to 0.1 and 0.01% O-2 was effectively eliminated following transfection with the pE9/iNOS construct. Significant inhibition of tumour growth was also observed in vivo following direct intratumoural injection of the pE9/iNOS construct compared to empty vector alone (P < 0.001) or to a single radiation dose of 10 Gy (P < 0.01). The combination of both therapies resulted in a significant 4.25 day growth delay compared to the gene therapy treatment alone (P < 0.001). In summary, we have demonstrated the potential of the pE9/ iNOS construct for reducing radio-resistance conferred by tumour cell hypoxia in vitro and in vivo, with greater tumour growth delay observed following the treatment with the gene therapy construct as compared with radiotherapy alone.
    LanguageEnglish
    Pages495-503
    JournalGene Therapy
    Volume15
    Issue number7
    DOIs
    Publication statusPublished - Apr 2008

    Fingerprint

    Nitric Oxide Synthase Type II
    Radiation
    Radio
    Transgenes
    Genetic Therapy
    X-Rays
    Neoplasms
    Growth
    Fibrosarcoma
    Neoplasm Genes
    Cytomegalovirus
    Sarcoma
    Transfection
    Radiotherapy
    Therapeutics
    Injections
    Genes
    In Vitro Techniques

    Cite this

    Coulter, J. A., McCarthy, H. O., Worthington, J., Robson, T., Scott, S., & Hirst, D. G. (2008). The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Therapy, 15(7), 495-503. https://doi.org/10.1038/gt.2008.7
    Coulter, J. A. ; McCarthy, H. O. ; Worthington, Jenny ; Robson, T. ; Scott, S. ; Hirst, D. G. / The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. In: Gene Therapy. 2008 ; Vol. 15, No. 7. pp. 495-503.
    @article{e26f72ca9ceb481785285851e522e829,
    title = "The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation",
    abstract = "Driving high-level transgene expression in a tumour-specific manner remains a key requirement in the development of cancer gene therapy. We have previously demonstrated the strong anticancer effects of generating abnormally high levels of intracellular NO center dot following the overexpression of the inducible nitric oxide synthase (iNOS) gene. Much of this work has focused on utilizing exogenously activated promoters, which have been primarily induced using X-ray radiation. Here we further examine the potential of the pE9 promoter, comprising a combination of nine CArG radio-responsive elements, to drive the iNOS transgene. Effects of X-ray irradiation on promoter activity were compared in vitro under normoxic conditions and various degrees of hypoxia. The pE9 promoter generated high-level transgene expression, comparable with that achieved using the constitutively driven cytomegalovirus promoter. Furthermore, the radio-resistance of radiation-induced fibrosarcoma-1 (RIF-1) mouse sarcoma cells exposed to 0.1 and 0.01{\%} O-2 was effectively eliminated following transfection with the pE9/iNOS construct. Significant inhibition of tumour growth was also observed in vivo following direct intratumoural injection of the pE9/iNOS construct compared to empty vector alone (P < 0.001) or to a single radiation dose of 10 Gy (P < 0.01). The combination of both therapies resulted in a significant 4.25 day growth delay compared to the gene therapy treatment alone (P < 0.001). In summary, we have demonstrated the potential of the pE9/ iNOS construct for reducing radio-resistance conferred by tumour cell hypoxia in vitro and in vivo, with greater tumour growth delay observed following the treatment with the gene therapy construct as compared with radiotherapy alone.",
    author = "Coulter, {J. A.} and McCarthy, {H. O.} and Jenny Worthington and T. Robson and S. Scott and Hirst, {D. G.}",
    year = "2008",
    month = "4",
    doi = "10.1038/gt.2008.7",
    language = "English",
    volume = "15",
    pages = "495--503",
    journal = "Gene Therapy",
    issn = "0969-7128",
    number = "7",

    }

    Coulter, JA, McCarthy, HO, Worthington, J, Robson, T, Scott, S & Hirst, DG 2008, 'The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation', Gene Therapy, vol. 15, no. 7, pp. 495-503. https://doi.org/10.1038/gt.2008.7

    The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. / Coulter, J. A.; McCarthy, H. O.; Worthington, Jenny; Robson, T.; Scott, S.; Hirst, D. G.

    In: Gene Therapy, Vol. 15, No. 7, 04.2008, p. 495-503.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation

    AU - Coulter, J. A.

    AU - McCarthy, H. O.

    AU - Worthington, Jenny

    AU - Robson, T.

    AU - Scott, S.

    AU - Hirst, D. G.

    PY - 2008/4

    Y1 - 2008/4

    N2 - Driving high-level transgene expression in a tumour-specific manner remains a key requirement in the development of cancer gene therapy. We have previously demonstrated the strong anticancer effects of generating abnormally high levels of intracellular NO center dot following the overexpression of the inducible nitric oxide synthase (iNOS) gene. Much of this work has focused on utilizing exogenously activated promoters, which have been primarily induced using X-ray radiation. Here we further examine the potential of the pE9 promoter, comprising a combination of nine CArG radio-responsive elements, to drive the iNOS transgene. Effects of X-ray irradiation on promoter activity were compared in vitro under normoxic conditions and various degrees of hypoxia. The pE9 promoter generated high-level transgene expression, comparable with that achieved using the constitutively driven cytomegalovirus promoter. Furthermore, the radio-resistance of radiation-induced fibrosarcoma-1 (RIF-1) mouse sarcoma cells exposed to 0.1 and 0.01% O-2 was effectively eliminated following transfection with the pE9/iNOS construct. Significant inhibition of tumour growth was also observed in vivo following direct intratumoural injection of the pE9/iNOS construct compared to empty vector alone (P < 0.001) or to a single radiation dose of 10 Gy (P < 0.01). The combination of both therapies resulted in a significant 4.25 day growth delay compared to the gene therapy treatment alone (P < 0.001). In summary, we have demonstrated the potential of the pE9/ iNOS construct for reducing radio-resistance conferred by tumour cell hypoxia in vitro and in vivo, with greater tumour growth delay observed following the treatment with the gene therapy construct as compared with radiotherapy alone.

    AB - Driving high-level transgene expression in a tumour-specific manner remains a key requirement in the development of cancer gene therapy. We have previously demonstrated the strong anticancer effects of generating abnormally high levels of intracellular NO center dot following the overexpression of the inducible nitric oxide synthase (iNOS) gene. Much of this work has focused on utilizing exogenously activated promoters, which have been primarily induced using X-ray radiation. Here we further examine the potential of the pE9 promoter, comprising a combination of nine CArG radio-responsive elements, to drive the iNOS transgene. Effects of X-ray irradiation on promoter activity were compared in vitro under normoxic conditions and various degrees of hypoxia. The pE9 promoter generated high-level transgene expression, comparable with that achieved using the constitutively driven cytomegalovirus promoter. Furthermore, the radio-resistance of radiation-induced fibrosarcoma-1 (RIF-1) mouse sarcoma cells exposed to 0.1 and 0.01% O-2 was effectively eliminated following transfection with the pE9/iNOS construct. Significant inhibition of tumour growth was also observed in vivo following direct intratumoural injection of the pE9/iNOS construct compared to empty vector alone (P < 0.001) or to a single radiation dose of 10 Gy (P < 0.01). The combination of both therapies resulted in a significant 4.25 day growth delay compared to the gene therapy treatment alone (P < 0.001). In summary, we have demonstrated the potential of the pE9/ iNOS construct for reducing radio-resistance conferred by tumour cell hypoxia in vitro and in vivo, with greater tumour growth delay observed following the treatment with the gene therapy construct as compared with radiotherapy alone.

    U2 - 10.1038/gt.2008.7

    DO - 10.1038/gt.2008.7

    M3 - Article

    VL - 15

    SP - 495

    EP - 503

    JO - Gene Therapy

    T2 - Gene Therapy

    JF - Gene Therapy

    SN - 0969-7128

    IS - 7

    ER -